533 related articles for article (PubMed ID: 29330358)
1. Pathogenesis of bone disease in multiple myeloma: from bench to bedside.
Terpos E; Ntanasis-Stathopoulos I; Gavriatopoulou M; Dimopoulos MA
Blood Cancer J; 2018 Jan; 8(1):7. PubMed ID: 29330358
[TBL] [Abstract][Full Text] [Related]
2. Osteocyte CIITA aggravates osteolytic bone lesions in myeloma.
Liu H; He J; Bagheri-Yarmand R; Li Z; Liu R; Wang Z; Bach DH; Huang YH; Lin P; Guise TA; Gagel RF; Yang J
Nat Commun; 2022 Jun; 13(1):3684. PubMed ID: 35760800
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma bone disease: Pathophysiology of osteoblast inhibition.
Giuliani N; Rizzoli V; Roodman GD
Blood; 2006 Dec; 108(13):3992-6. PubMed ID: 16917004
[TBL] [Abstract][Full Text] [Related]
4. Pathogenesis of myeloma bone disease.
Roodman GD
J Cell Biochem; 2010 Feb; 109(2):283-91. PubMed ID: 20014067
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic Mechanisms of Myeloma Bone Disease and Possible Roles for NRF2.
Yen CH; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937821
[TBL] [Abstract][Full Text] [Related]
6. Host-Derived Matrix Metalloproteinase-13 Activity Promotes Multiple Myeloma-Induced Osteolysis and Reduces Overall Survival.
Lo CH; Shay G; McGuire JJ; Li T; Shain KH; Choi JY; Fuerst R; Roush WR; Knapinska AM; Fields GB; Lynch CC
Cancer Res; 2021 May; 81(9):2415-2428. PubMed ID: 33526510
[TBL] [Abstract][Full Text] [Related]
7. Myeloma bone disease: recent advances in biology, diagnosis, and treatment.
Sezer O
Oncologist; 2009 Mar; 14(3):276-83. PubMed ID: 19286761
[TBL] [Abstract][Full Text] [Related]
8. Receptor activator of nuclear factor-kappaB ligand expression by human myeloma cells mediates osteoclast formation in vitro and correlates with bone destruction in vivo.
Farrugia AN; Atkins GJ; To LB; Pan B; Horvath N; Kostakis P; Findlay DM; Bardy P; Zannettino AC
Cancer Res; 2003 Sep; 63(17):5438-45. PubMed ID: 14500379
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of bone destruction in multiple myeloma.
Terpos E; Christoulas D; Gavriatopoulou M; Dimopoulos MA
Eur J Cancer Care (Engl); 2017 Nov; 26(6):. PubMed ID: 28940410
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis and management of myeloma bone disease.
Christoulas D; Terpos E; Dimopoulos MA
Expert Rev Hematol; 2009 Aug; 2(4):385-98. PubMed ID: 21082944
[TBL] [Abstract][Full Text] [Related]
11. Bidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple Myeloma.
Delgado-Calle J; Anderson J; Cregor MD; Hiasa M; Chirgwin JM; Carlesso N; Yoneda T; Mohammad KS; Plotkin LI; Roodman GD; Bellido T
Cancer Res; 2016 Mar; 76(5):1089-100. PubMed ID: 26833121
[TBL] [Abstract][Full Text] [Related]
12. Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.
Deligiorgi MV; Panayiotidis MI; Griniatsos J; Trafalis DT
Clin Exp Metastasis; 2020 Feb; 37(1):13-30. PubMed ID: 31578655
[TBL] [Abstract][Full Text] [Related]
13. Emerging treatment approaches for myeloma-related bone disease.
Gavriatopoulou M; Dimopoulos MA; Kastritis E; Terpos E
Expert Rev Hematol; 2017 Mar; 10(3):217-228. PubMed ID: 28092987
[TBL] [Abstract][Full Text] [Related]
14. Glycosphingolipid synthesis inhibition limits osteoclast activation and myeloma bone disease.
Ersek A; Xu K; Antonopoulos A; Butters TD; Santo AE; Vattakuzhi Y; Williams LM; Goudevenou K; Danks L; Freidin A; Spanoudakis E; Parry S; Papaioannou M; Hatjiharissi E; Chaidos A; Alonzi DS; Twigg G; Hu M; Dwek RA; Haslam SM; Roberts I; Dell A; Rahemtulla A; Horwood NJ; Karadimitris A
J Clin Invest; 2015 Jun; 125(6):2279-92. PubMed ID: 25915583
[TBL] [Abstract][Full Text] [Related]
15. Pathogenesis and Treatment of Myeloma-Related Bone Disease.
Gau YC; Yeh TJ; Hsu CM; Hsiao SY; Hsiao HH
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328533
[TBL] [Abstract][Full Text] [Related]
16. An Evidence-Based Approach to Myeloma Bone Disease.
Bingham N; Reale A; Spencer A
Curr Hematol Malig Rep; 2017 Apr; 12(2):109-118. PubMed ID: 28243849
[TBL] [Abstract][Full Text] [Related]
17. Myeloma and bone disease: "the dangerous tango".
Epstein J; Walker R
Clin Adv Hematol Oncol; 2006 Apr; 4(4):300-6. PubMed ID: 16728940
[TBL] [Abstract][Full Text] [Related]
18. Biological aspects of altered bone remodeling in multiple myeloma and possibilities of pharmacological intervention.
Kupisiewicz K
Dan Med Bull; 2011 May; 58(5):B4277. PubMed ID: 21535989
[TBL] [Abstract][Full Text] [Related]
19. Cellular mechanisms of multiple myeloma bone disease.
Oranger A; Carbone C; Izzo M; Grano M
Clin Dev Immunol; 2013; 2013():289458. PubMed ID: 23818912
[TBL] [Abstract][Full Text] [Related]
20. Possible targets to treat myeloma-related osteoclastogenesis.
Bolzoni M; Toscani D; Storti P; Marchica V; Costa F; Giuliani N
Expert Rev Hematol; 2018 Apr; 11(4):325-336. PubMed ID: 29495905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]